Intervest — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
OncoResponseoncoresponseinc.comMay 2023 · $14M
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersARCH Venture PartnersBering Capital+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.